2019
DOI: 10.1016/j.xphs.2019.07.023
|View full text |Cite
|
Sign up to set email alerts
|

Development of Dexlansoprazole Delayed-Release Capsules, a Dual Delayed-Release Proton Pump Inhibitor

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
9
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 10 publications
(9 citation statements)
references
References 15 publications
0
9
0
Order By: Relevance
“…Time-dependent drug release can also be achieved via preparation of two different enteric-coated granules, one that dissolves in the upper intestine and the other that dissolves in the lower intestine. The Food and drug administration (FDA) has approved a dual delayed-release formulation of dexlansoprazole comprised of two types of enteric-coated granules with different pH-dependent dissolution profiles, one released at 1–2 h after dosing and the other released at 5–6 h after dosing [ 47 , 48 ]. This formulation in a once-daily dosing is effective to extend drug absorption and control intragastric acidity for longer periods of time [ 47 , 48 ].…”
Section: Pharmaceutical Application Of Film Coatingmentioning
confidence: 99%
“…Time-dependent drug release can also be achieved via preparation of two different enteric-coated granules, one that dissolves in the upper intestine and the other that dissolves in the lower intestine. The Food and drug administration (FDA) has approved a dual delayed-release formulation of dexlansoprazole comprised of two types of enteric-coated granules with different pH-dependent dissolution profiles, one released at 1–2 h after dosing and the other released at 5–6 h after dosing [ 47 , 48 ]. This formulation in a once-daily dosing is effective to extend drug absorption and control intragastric acidity for longer periods of time [ 47 , 48 ].…”
Section: Pharmaceutical Application Of Film Coatingmentioning
confidence: 99%
“…The studies of dexlansoprazole modified release (MR) 30 and 60 mg (Dexilant, Takeda Pharmaceuticals) showed that the DR formulation maintained a higher mean intragastric pH and percentage of time with intragastric pH over 4 (%Time over pH 4) with a longer period of the plasma exposure when compared to the conventional formulation in a once-daily dosing regimen. 14 , 15 …”
Section: Introductionmentioning
confidence: 99%
“…11 Esomeprazole (S-enantiomer of omeprazole) and dexlansoprazole (R-enantiomer of lansoprazole), respectively, showed higher bioavailability and lower clearance than the racemic mixtures, omeprazole and lansoprazole. [11][12][13][14] Enteric-coated (EC) delayed-release formulations are commonly used for acid-labile PPIs to prevent degradation by gastric acid, but there are still limitations regarding the PKs of the PPIs themselves or the physiology of the proton pump. [2][3][4][5][6] Twice-daily PPI therapy is considered an option for some patients with GERD, but the frequency of doses may affect the patient compliance.…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…Among these, in the family of proton pump inhibitors [ 14 , 15 ] omeprazole was the best-selling drug in the treatment of gastric acid hypersecretion, but the superior clinical efficacy (improved bioavailability, acid control, healing and symptoms resolution) proved for its ( S )-enantiomer esomeprazole [ 16 , 17 ] led to a growing market for this drug compared to the original formulation containing the racemic molecule. More recently, dexlansoprazole, the ( R )-enantiomer of lansoprazole, was launched on the market in a dual delayed-release formulation able to maintain a more prolonged drug exposure in human plasma compared to the parent racemic drug [ 18 ].…”
Section: Introductionmentioning
confidence: 99%